 |
Rigel Pharmaceuticals RIGL (news,
chart,
quote) - RIGL option Implied Volatility is high at 198
RIGL Phase 2B trail data examining R112 (a nasal-administered Syk kinase inhibitor) in an allergic rhinitis setting is expected in December. RIGL December option implied volatility of 198 is above its 6-month average of 75. RIGL intra-day call option volume of 2,028 contracts compares to intra-day put volume of 2,407 contracts. High option implied volatility suggests larger price risk.
|
|
|
|
